The Clinical Trials on Alzheimer's Disease (CTAD) conference kicks off in San Francisco this week and ATRI leadership, along with our fellow Alzheimer's Clinical Trials Consortium (ACTC) members, are involved with many of the sessions. The sessions will provide insight into some of the work being done by ACTC members and collaborators.
Below you'll find a list of key sessions the ATRI leadership helped make possible. ATRI's Dr. Paul Aisen will also be giving the introduction at the opening ceremony.
Development and Feasibility of a Data-Driven Approach to Preclinical Alzheimer’s Disease Clinical Trial Recruitment through Centralized Pre-screening
— Includes Paul Aisen, Rema Raman, and Gustavo Jimenez-Maggiora.
Long-Term Nicotine Treatment of Mild Cognitive Impairment (The MIND Study): Baseline Characteristics and Study Progress
— Includes Paul Aisen and Rema Raman.
The AlzMatch Study: Remote Plasma Acquisition to Pre-screen for Preclinical Alzheimer's Disease Trials
— Includes Paul Aisen, Rema Raman, Michael Donohue, Robert Rissman and Gustavo Jimenez-Maggiora.
Evaluation of blood-based plasma biomarkers as potential markers of amyloid burden in preclinical Alzheimer’s Disease
— Includes Paul Aisen, Rema Raman, Michael Donohue and Robert Rissman.
Impact of Alzheimer’s Disease Biomarker Disclosure to Cognitively Unimpaired Individuals: Experiences from a Truncated Randomized Phase 2b/3 Clinical Trial
— Includes Paul Aisen, Rema Raman and Michael Donohue.
Assessing Clinically Meaningful Functional Outcomes in Preclinical Alzheimer’s Disease
— Includes Paul Aisen, Rema Raman and Michael Donohue.
Disease Progression Modelling Identified MRI-based Subtypes with Cognitive Heterogeneity in A4 Study Preclinical Trial Cohort
— Includes Michael Donohue.
To see the entire CTAD conference schedule click here.
